Results 141 to 150 of about 15,976 (198)

Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

open access: green, 2008
Lazaros Konstantinidis   +4 more
openalex   +2 more sources

Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study

open access: gold, 2015
Winfried M. K. Amoaku   +6 more
openalex   +2 more sources

Predictive Factors for Macular Atrophy in Patients with Treated Myopic Macular Neovascularization. [PDF]

open access: yesClin Ophthalmol
Ferreira AM   +6 more
europepmc   +1 more source

Video Color OCT Angiography for Myopic Choroidal Neovascularization

Ophthalmology Retina
To investigate the myopic macular neovascularization (mMNV) features on dynamic video color OCT angiography (OCTA) and the diagnostic rate versus the static, 4-segmentations visualization mode.Retrospective cohort study.Fifty-four patients with mMNV.Sixty-two eyes with high myopia complicated by mMNV were included.
Paolo Milani   +9 more
openaire   +3 more sources

Ranibizumab for myopic choroidal neovascularization

Expert Opinion on Biological Therapy, 2020
Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic ...
Danny S C, Ng   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy